Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Verträglichkeit (9 Abbildungen)
Übersicht


Zum ersten Bild Abb. 2: Telmisartan - Placebo - Verträglichkeit Abb. 3: Telmisartan - Verträglichkeit Abb. 4: Telmisartan - HCTZ - Verträglichkeit Abb. 5: Verträglichkeitsprofil Aktuelles Bild - Abb. 6: Verträglichkeitsprofil Abb. 7: Verträglichkeitsprofil Abb. 8: HCTZ - Hypokaliämische Einflüsse Abb. 9: Verträglichkeit
Abbildung 6: Verträglichkeitsprofil
In this study, 578 patients with mild-to-moderate hypertension received telmisartan 40–160 mg or lisinopril 10–40 mg once daily for 52 weeks.1 At the end of the maintenance period, mean SBP/ DBP reductions were 23.8/16.6 mmHg and 19.9/15.6 mmHg in the telmisartan and lisinopril arms, respectively. Treatment-related side effects occurred in fewer telmisartan-treated patients (28%) than in lisinopril-treated patients (40%, P=0.001), principally due to an increase in cough with lisinopril. There were also two cases of angioedema, both in the lisinopril group. Similar results were seen in an 8-week comparison of telmisartan with enalapril in 86 patients with severe hypertension.2 No patients on telmisartan experienced cough during this study, compared with 7% of patients on enalapril. Neutel JM, Frishman WH, Oparil S, et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Therapeutics 1999; 6: 161–166. Neutel JM, Smith DHG, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract 1999; 53: 175–178.
 
Verträglichkeitsprofil
Vorheriges Bild Nächstes Bild   


Abbildung 6: Verträglichkeitsprofil
In this study, 578 patients with mild-to-moderate hypertension received telmisartan 40–160 mg or lisinopril 10–40 mg once daily for 52 weeks.1 At the end of the maintenance period, mean SBP/ DBP reductions were 23.8/16.6 mmHg and 19.9/15.6 mmHg in the telmisartan and lisinopril arms, respectively. Treatment-related side effects occurred in fewer telmisartan-treated patients (28%) than in lisinopril-treated patients (40%, P=0.001), principally due to an increase in cough with lisinopril. There were also two cases of angioedema, both in the lisinopril group. Similar results were seen in an 8-week comparison of telmisartan with enalapril in 86 patients with severe hypertension.2 No patients on telmisartan experienced cough during this study, compared with 7% of patients on enalapril. Neutel JM, Frishman WH, Oparil S, et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Therapeutics 1999; 6: 161–166. Neutel JM, Smith DHG, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract 1999; 53: 175–178.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung